The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I/II study of biweekly docetaxel (D) in combination with fixed-dose cisplatin plus fluorouracil (CF) in patients (pts) with advanced esophageal cancer (AEC) (JCOG0807).
Shuichi Hironaka
No relevant relationships to disclose
Yasuhiro Tsubosa
No relevant relationships to disclose
Junki Mizusawa
No relevant relationships to disclose
Takayuki Kii
No relevant relationships to disclose
Ken Kato
Research Funding - Daiichi Sankyo; Shionogi
Takahiro Tsushima
No relevant relationships to disclose
Keisho Chin
No relevant relationships to disclose
Akihisa Tomori
No relevant relationships to disclose
Tatsuya Okuno
No relevant relationships to disclose
Toshikatsu Taniki
No relevant relationships to disclose
Takashi Ura
No relevant relationships to disclose
Hisayuki Matsushita
No relevant relationships to disclose
Takashi Kojima
No relevant relationships to disclose
Yuichiro Doki
No relevant relationships to disclose
Kazumasa Fujitani
No relevant relationships to disclose
Koichi Taira
No relevant relationships to disclose
Shiko Seki
No relevant relationships to disclose
Tsutomu Nakamura
No relevant relationships to disclose
Yuko Kitagawa
Honoraria - Sanofi
Research Funding - Sanofi